Request Demo
Last update 19 Sep 2026
CD19-CAR-DNT Cells
Last update 19 Sep 2026
Overview
Basic Info
Drug Type Universal CAR-T |
Synonyms RJMty19 |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
4
Clinical Trials associated with CD19-CAR-DNT CellsNCT06314828
A Phase 1, Open-label, Single Arm Clinical Trial to Evaluate the Tolerability, Safety and Efficacy of RJMty19 in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
NCT06340490
A Phase I Clinical Trial of RJMty19 in Treatment of Subjects With Refractory Systemic Lupus Erythematosus
NCT06316076
A Clinical Study for the Safety and Efficacy of CD19-CAR-DNT Cells (RJMty19) in the Treatment of Relapsed or Refractory Autoimmune Diseases
100 Clinical Results associated with CD19-CAR-DNT Cells
Login to view more data
100 Translational Medicine associated with CD19-CAR-DNT Cells
Login to view more data
100 Patents (Medical) associated with CD19-CAR-DNT Cells
Login to view more data
100 Deals associated with CD19-CAR-DNT Cells
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| B-cell lymphoma recurrent | Phase 1 | China | 17 Jun 2024 | |
| B-cell lymphoma refractory | Phase 1 | - | 20 May 2024 | |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 1 | China | 30 Oct 2023 | |
| Idiopathic Inflammatory Myopathies | Phase 1 | China | 30 Oct 2023 | |
| Scleroderma, Systemic | Phase 1 | China | 30 Oct 2023 | |
| Systemic Lupus Erythematosus | Phase 1 | China | 30 Oct 2023 | |
| CD19-positive B-cell acute lymphoblastic leukemia | IND Approval | China | 05 Mar 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
CTR20241469 (NEWS) Manual  | Phase 1 | 11 | (高剂量单次给药) | evpkoalfpj(ndxiexpvqj) = 所有受试者的安全性良好，未观察到≥3级细胞因子风暴、神经毒性或移植物抗宿主反应 utwewxmcdm (iphteykbek ) | Positive | 03 Jul 2025 | |
(多次给药) | |||||||
NCT05453669 (NEWS) Manual | Phase 1 | 12 | (第4剂量组) | wfneoqigqm(gnnbxfjdxu) = hrckbjvxsd fyljekfeyj (kgnjuetsza ) View more | Positive | 24 Aug 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free